In this study, pharmacogenomics and therapeutic drug ... polymorphisms in CYP2D6 that make them poor or intermediate metabolizers of opioid medications would have higher steady-state ...

Based on the rate of metabolism of CYP2C19 substrates, three groups can be distinguished depending on their genotype: rapid metabolizers (with an increased enzyme activity), intermediate ...

The scientific terms for these two determinants are pharmacokinetics and pharmacodynamics, and both are critical considerations in the field of pharmacogenomics. Pharmacokinetics encompasses four ...

The number of pharmacogenetic tests available within NHS England is expected to increase. Spain is making significant strides in integrating pharmacogenomics into its healthcare system by introducing ...

The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the importance of discussing it.